Welcome to our dedicated page for PIERIS PHARMACEUTICALS news (Ticker: PIRS), a resource for investors and traders seeking the latest updates and insights on PIERIS PHARMACEUTICALS stock.
Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) is a clinical-stage biotechnology company dedicated to developing novel Anticalin-based drugs. These drugs target specific disease pathways in innovative and transformative ways. The company's proprietary Anticalin proteins are engineered versions of human lipocalins, which naturally bind, store, and transport a wide range of molecules. This unique technology has been validated through clinical trials and partnerships with leading pharmaceutical companies.
Core Business and Products
Pieris specializes in creating a diverse pipeline of Anticalin-based therapeutics. Their current focus areas include:
- Immuno-Oncology: Multi-specifics tailored for the tumor micro-environment, such as PRS-344 targeting PD-L1 and 4-1BB, PRS-346 targeting CD228 and 4-1BB, and PRS-342 targeting GPC3 and 4-1BB.
- Respiratory Diseases: Inhaled Anticalin proteins to treat conditions like uncontrolled asthma, with ongoing projects such as elarekibep, an inhaled IL-4 receptor alpha inhibitor.
- Other Conditions: Including treatment for anemia through half-life-optimized Anticalin proteins.
Recent Achievements and Partnerships
Pieris continues to make significant strides in its research and development efforts. Despite recent setbacks such as AstraZeneca's decision to discontinue studies on elarekibep, Pieris is actively reassessing its corporate priorities and focusing on leveraging its strong partnerships with companies like Roche, Pfizer, Boston Pharmaceuticals, and Servier.
Financial Condition and Strategic Focus
As of June 30, 2023, Pieris reported cash, cash equivalents, and investments totaling approximately $54.9 million. The company has initiated a corporate restructuring to reduce workforce and operational costs, aiming to extend its cash runway. Pieris is also exploring strategic options, including new partnerships and potential acquisitions, to maximize shareholder value.
For more detailed information, visit www.pieris.com.
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) announced an upcoming investor call on November 2, 2022, at 8:00 AM EDT. The call will focus on third-quarter 2022 financial results and corporate updates. Participants can join the call by dialing (888) 645-4404 (Toll Free) or (862) 298-0702 (International). A listen-only audio webcast will also be available here. For those unable to attend, a replay will be accessible on the company's website.
Pieris Pharmaceuticals (NASDAQ:PIRS), a clinical-stage biotech firm, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 12:30 PM EDT. The presentation will highlight its proprietary Anticalin technology for treating respiratory diseases and cancer. A webcast will be available here. The company focuses on developing inhalable Anticalin proteins and locally-activated bispecifics for improved clinical outcomes. For more details, visit www.pieris.com.
Pieris Pharmaceuticals (NASDAQ:PIRS) has announced the presentation of preclinical data for its inhaled drug candidate PRS-400 at the ERS International Congress 2022. This candidate targets muco-obstructive lung diseases by inhibiting Jagged-1, a protein involved in mucus regulation. Preclinical results indicate that PRS-400 effectively reduces mucin expression and goblet cell presence in models of airway inflammation. Pieris aims to leverage these findings to advance PRS-400 and its Anticalin technology for broader respiratory disease applications.
Pieris Pharmaceuticals reported its Q2 2022 financial results, revealing a net loss of $10.3 million, or $(0.14) per share, an improvement from a loss of $15.5 million in Q2 2021. The company is adjusting its PRS-060/AZD1402 trial design to boost enrollment and aims for topline results by Q3 2023. Pieris will cease enrollment in the cinrebafusp alfa study to prioritize resources. The company has submitted regulatory filings for PRS-220 and anticipates dosing the first patient later this year, with cash reserves expected to fund operations until Q2 2024.
Pieris Pharmaceuticals (NASDAQ:PIRS) will host a second quarter 2022 investor call on August 4, 2022, at 8:00 AM EDT. The call will cover financial results and provide a corporate update. Participants can join by dialing (800) 285-6670 for US & Canada or (713) 481-1320 internationally, at least five minutes prior. A listen-only audio webcast will also be available. A replay will be posted on the company’s website for those unable to attend. For more information, visit pieris.com.
Pieris Pharmaceuticals (NASDAQ:PIRS), a clinical-stage biotechnology company, announced its management will present at the Jefferies Healthcare Conference on June 8, 2022, at 8:00 AM EDT. The presentation will showcase their innovative Anticalin technology aimed at treating respiratory diseases and cancer.
The company specializes in developing biotherapeutics, including inhalable Anticalin proteins and locally-activated bispecifics for immuno-oncology. A webcast of the presentation will be available via their website.
Pieris Pharmaceuticals (NASDAQ:PIRS) will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 9:30 AM EDT. The presentation will be available via webcast at the provided link. The company focuses on developing innovative biotherapeutics using its unique Anticalin technology platform, targeting respiratory diseases and cancer. Pieris aims to create inhalable Anticalin proteins for respiratory issues and bispecifics for immuno-oncology, showcasing its commitment to delivering superior clinical outcomes.
Pieris Pharmaceuticals (NASDAQ: PIRS) reported its first-quarter financial results for 2022, revealing revenues of $10.99 million, down from $15.63 million in Q1 2021. The company's net loss was $5.1 million or $(0.07) per share, consistent with the previous year's loss. Cash reserves decreased to $100.3 million. Despite challenges affecting clinical enrollments, Pieris remains committed to advancing its pipeline, including the IND filing for PRS-342/BOS-342 expected within the next 12 months and ongoing collaborations with AstraZeneca.
BOSTON, MA / ACCESSWIRE / May 4, 2022 - Pieris Pharmaceuticals (NASDAQ:PIRS) will host a first quarter 2022 investor call on May 11, 2022, at 8:00 AM EDT. The call will cover financial results and provide a corporate update.
Participants can join by dialing (888) 428-7458 for the US or (862) 298-0702 internationally, or listen via a webcast here. A replay will be available after the call on the company's website.
Pieris Pharmaceuticals reported financial results for the year ended December 31, 2021, revealing a net loss of $45.7 million or $(0.71) per share. Cash and equivalents reached $117.8 million, an increase from $70.4 million in 2020, supported by collaboration agreements and an ATM program raising $38.5M. The company initiated several clinical trials, including phase 2 studies of PRS-060/AZD1402 and cinrebafusp alfa, with topline data expected this year. The R&D expense rose to $66.7 million, reflecting higher spending on multiple programs.
FAQ
What is the current stock price of PIERIS PHARMACEUTICALS (PIRS)?
What is the market cap of PIERIS PHARMACEUTICALS (PIRS)?
What does Pieris Pharmaceuticals specialize in?
What are Anticalin proteins?
What is the focus of Pieris' pipeline?
What recent developments has Pieris faced?
Who are Pieris' key partners?
What is Pieris' financial strategy?
What is the status of Pieris' clinical trials?
How has Pieris responded to its recent challenges?
Where is Pieris Pharmaceuticals located?
How can investors get more information about Pieris?
